




Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

Mark Toshner ^{(1,2,20}, Colin Church^{3,20}, Lars Harbaum⁴, Christopher Rhodes⁴, Sofia S. Villar Moreschi⁵, James Liley^{1,5}, Rowena Jones¹, Amit Arora⁶, Ken Batai⁷, Ankit A. Desai⁸, John G. Coghlan⁹, J. Simon R. Gibbs⁴, Dee Gor¹⁰, Stefan Gräf ⁽¹⁾, Louise Harlow², Jules Hernandez-Sanchez¹⁰, Luke S. Howard ⁽¹⁾, Marc Humbert ⁽¹⁾, Jason Karnes⁶, David G. Kiely ⁽¹⁾, Rick Kittles⁶, Emily Knightbridge¹, Brian Lam¹³, Katie A. Lutz¹⁴, William C. Nichols¹⁴, Michael W. Pauciulo¹⁴, Joanna Pepke-Zaba², Jay Suntharalingam¹⁵, Florent Soubrier ⁽¹⁾, Richard C. Trembath¹⁷, Tae-Hwi L. Schwantes-An⁸, S. John Wort⁴, Martin R. Wilkins ⁽¹⁾, Sean Gaine¹⁸, Nicholas W. Morrell^{1,21} and Paul A. Corris^{19,21}, the Uniphy Clinical Trials Network

¹Dept of Medicine, University of Cambridge, Cambridge, UK. ²Royal Papworth Hospital, Cambridge, UK. ³Golden Jubilee Hospital, Glasgow, UK. ⁴Heart Lung Research Institute, Imperial College, London, UK. ⁵MRC Biostatistical Unit, University of Cambridge, Cambridge, UK. ⁶Dept of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA. ⁷Dept of Urology, University of Arizona, Tucson, AZ, USA. ⁸Dept of Medicine, Indiana University, Indianapolis, IN, USA. ⁹Royal Free Hospital, London, UK. ¹⁰Roche Products Limited, Welwyn Garden City, UK. ¹¹Université Paris-Sud, Le Kremlin-Bicêtre, Paris, France. ¹²Royal Hallamshire Hospital, Sheffield, UK. ¹³Institute of Metabolic Sciences, University of Cambridge, Cambridge, UK. ¹⁴Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. ¹⁵Royal United Hospital, Bath, UK. ¹⁶Sorbonne Universités, INSERM, Paris, France. ¹⁷Genetics and Molecular Medicine, King's College, London, UK. ¹⁸Mater Misericordiae University Hospital, Dublin, Ireland. ¹⁹Dept of Medicine, Newcastle University, Newcastle, UK. ²⁰Authors contributed equally to this work. ²¹Authors contributed equally to this work.

Corresponding author: Mark Toshner (mrt34@medschl.cam.ac.uk)



predict treatment response. Mendelian randomisation did not support an effect of the lead *IL6R* variant on risk of PAH (OR 0.99, p=0.88).

Conclusion Adverse events were consistent with the known safety profile of tocilizumab. Tocilizumab did not show any consistent treatment effect.